LRMR - NASDAQ

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.30

-3.0%
HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$282.41M
EPS-2.2700
P/E Ratio-1.68
Earnings Date08/06/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Earnings Call Transcripts

LRMR · NASDAQ

2023

1
Q1
Sep 29
Q2
N/A
Q3
N/A
Q4
N/A

Related Guides

Blog Categories

Continue your LRMR research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.